Abstract:Purpose: It has become increasingly clear that the activation of both the innate and adaptive immune systems is vital to provide the best outcomes with immunotherapies. As part of the adaptive immune response, checkpoint inhibitors (CIs) have shown promise in the clinic, but seem to only work in a small subset of cancers with response rates below 20%. It is anticipated that activation of the innate immune response may help sensitize multiple cancer types to adaptive immune therapies. cGAS-STING pathway, which is activated in response to cytosolic DNA, has emerged as a key mechanism to activate innate immunity, primarily through type I interferon (IFN) signaling. Several direct STING agonists have been developed but their performance in the clinic has been dissatisfactory. A key limitation with direct STING agonists is the widespread expression of STING in normal tissues, whereby the hyperactivation of STING can lead to a systemic cytokine storm. Thus, there is a need to identify alternative approaches to activate STING in a controlled manner. ENPP1 is the only known direct negative regulator of the STING pathway that hydrolyzes 2′3′ cGAMP, the direct ligand of STING. Highest levels of 2′3′ cGAMP are found in tumors and recent evidence suggests that 2′3′ cGAMP acts locally, as a paracrine immune transmitter. Therefore, inhibition of ENPP1 may produce superior outcomes by activating STING in the tumor microenvironment. Previously, we reported the development of SR-8541A, a highly selective and potent inhibitor of ENPP1 that activates the STING pathway. Here, we show that the inhibition of ENPP1 with SR-8541A enhances the effect of CIs in breast and colon cancer models. Methods: Immune infiltration assays were conducted using human breast cancer cell line derived organoids (MDA-MB-231 and MDA-MB-468). Co-cultures of cancer organoids and immune cells (PBMCs) were exposed to SR-8541A +/- CIs (CTLA-4 and/or PD-1) for 48 hours. Confocal Z-Stack imaging, RT-PCR, and MSD cytokine assays were performed to evaluate the effects. In vivo studies were conducted using syngeneic mouse models (CT-26 and EMT-6), which were engrafted subcutaneously and treated with SR-8541A +/- CIs. Tumor growth was monitored over the course of the study. IHC and RT-PCR were conducted on the tumors. Results: Combination of SR-8541A with CIs showed a significant increase in immune infiltration in both the MDA-MB-231 and MDA-MB-468 organoid models. Corresponding RT-PCR analysis showed activation of IFN signaling (IFN-ß, CXCL10, ISG15). In vivo combination with CIs also exhibited a significant increase in overall efficacy, along with increased levels of CD3+ and CD8+ T-cell infiltration into the tumors, and increased levels of IFN response. Conclusion: In summary, we show that combination of ENPP1 inhibition with checkpoint inhibition promotes a robust antitumor activity by stimulating both innate and adaptive immune response. Citation Format: Alexis S. Weston, Trason Thode, Serina Ng, Tithi Ghosh-Halder, Shelby Rheinschmidt, Sydney Adamson, Katelyn Gutowsky, Brian Durbin, Raffaella Soldi, Srinivas Kasibhatla, Mohan Kaadige, Sunil Sharma. Inhibition of ENPP1 using small molecule, SR-8541A, enhances the effect of checkpoint inhibition in cancer models [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 2 (Clinical Trials and Late-Breaking Research); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(8_Suppl) nr LB323.

Re-awakening Innate Immune Signaling in Cancer: The Development of Highly Potent ENPP1 Inhibitors

Targeting ENPP1 for cancer immunotherapy: Killing two birds with one stone

ENPP1 Immunobiology as a Therapeutic Target

ENPP1 is an innate immune checkpoint of the anticancer cGAMP-STING pathway

Abstract 702: A novel small molecule inhibitor of ENPP1 promotes T and NK cell activation and enhances anti-tumor efficacy in combination with immune checkpoint blockade therapy

Synthetic Enforcement of STING Signaling in Cancer Cells Appropriates the Immune Microenvironment for Checkpoint Inhibitor Therapy.

Structure-aided development of small molecule inhibitors of ENPP1, the extracellular phosphodiesterase of the immunotransmitter cGAMP

Development of Novel Ecto-Nucleotide Pyrophosphatase/Phosphodiesterase 1 (ENPP1) Inhibitors for Tumor Immunotherapy

ENPP1 is an innate immune checkpoint of the anticancer cGAMP-STING pathway in breast cancer

Identification of the extracellular membrane protein ENPP3 as a major cGAMP hydrolase and innate immune checkpoint

Identification of extracellular membrane protein ENPP3 as a major cGAMP hydrolase, cementing cGAMP’s role as an immunotransmitter

Tumor Immune Checkpoints and Their Associated Inhibitors

Design, synthesis and biological evaluation studies of novel small molecule ENPP1 inhibitors for cancer immunotherapy

Identification of extracellular membrane protein ENPP3 as a major cGAMP hydrolase, cementing cGAMP's role as an immunotransmitter

Discovery of Pyrido[2,3- d ]pyrimidin-7-one Derivatives as Highly Potent and Efficacious Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (ENPP1) Inhibitors for Cancer Treatment

Ecto-nucleotide pyrophosphatase/phosphodiesterase 1 inhibitors: Research progress and prospects

A novel small molecule Enpp1 inhibitor improves tumor control following radiation therapy by targeting stromal Enpp1 expression

Abstract LB323: Inhibition of ENPP1 using small molecule, SR-8541A, enhances the effect of checkpoint inhibition in cancer models

Abstract 411: PI3K-AKT-mTOR signaling pathways play important roles in chromosomal instability-induced innate immune response in cancer cells

Metastasis and Immune Evasion from Extracellular cGAMP Hydrolysis

Discovery of Imidazo[1,2- a ]pyrazine Derivatives as Potent ENPP1 Inhibitors